The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist.
Open accessAbstract
Catecholamine secretory vesicle core proteins (chromogranins) contain an activity that inhibits catecholamine release, but the identity of the responsible peptide has been elusive. Size-fractionated chromogranins antagonized nicotinic cholinergic-stimulated catecholamine secretion; the inhibitor was enriched in processed chromogranin fragments, and was liberated from purified chromogranin A. Of 15 synthetic peptides spanning approximately 80% of chromogranin A, one (bovine chromogranin A344-364 [RSMRLSFRARGYGFRGPGLQL], or catestatin) was a potent, dose-dependent (IC50 approximately 200 nM), reversible secretory inhibitor on pheochromocytoma and adrenal chromaffin cells, as well as noradrenergic neurites. An antibody directed against this peptide blocked the inhibitory effect of chromogranin A proteolytic fragments on nicotinic-stimulated catecholamine secretion. This region of chromogranin A is extensively processed within chromaffin vesicles in vivo. The inhibitory effect was specific for nicotinic cholinergic stimulation of catecholamine release, and was shared by this chromogranin A region from several species. Nicotinic cationic (Na+, Ca2+) signal transduction was specifically disrupted by catestatin. Even high-dose nicotine failed to overcome the inhibition, suggesting noncompetitive nicotinic antagonism. This small domain within chromogranin A may contribute to a novel, autocrine, homeostatic (negative-feedback) mechanism controlling catecholamine release from chromaffin cells and neurons.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302
Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide
Merrifield, R. B. (1963) · Journal of the American Chemical Society · doi:10.1021/ja00897a025 · Cited by 7,647
Greene, L. A., & Tischler, A. S. (1976) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.73.7.2424 · Cited by 5,553
Molloy, S. S., Bresnahan, P. A., Leppla, S. H., Klimpel, K. R., & Thomas, G. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42016-9 · Cited by 689
Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion
Tatemoto, K., Efendić, S., Mutt, V., Makk, G., Feistner, G. J., & Barchas, J. D. (1986) · Nature · doi:10.1038/324476a0 · Cited by 681
The chromogranins A and B: The first 25 years and future perspectives
Winkler, H., & Fischer-Colbrie, R. (1992) · Neuroscience · doi:10.1016/0306-4522(92)90222-n · Cited by 655
BLASCHKO, H., COMLINE, R. S., SCHNEIDER, F. H., SILVER, M., & SMITH, A. D. (1967) · Nature · doi:10.1038/215058a0 · Cited by 520
Secretion of Chromogranin A by Peptide-Producing Endocrine Neoplasms
O'Connor, D. T., & Deftos, L. J. (1986) · New England Journal of Medicine · doi:10.1056/nejm198605013141803 · Cited by 477
Self-citationThe molecular function of adrenal chromaffin granules: Established facts and unresolved topics
Winkler, H., Apps, D. K., & Fischer-Colbrie, R. (1986) · Neuroscience · doi:10.1016/0306-4522(86)90154-5 · Cited by 354
The primary structure of human chromogranin A and pancreastatin.
Konecki, D. S., Benedum, U. M., Gerdes, H. H., & Huttner, W. B. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)45486-5 · Cited by 288
Cited by
The Chromogranin–Secretogranin Family
Taupenot, L., Harper, K. L., & O'Connor, D. T. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021405 · Cited by 819
Self-citationThe Extended Granin Family: Structure, Function, and Biomedical Implications
Bartolomucci, A., Possenti, R., Mahata, S. K., Fischer-Colbrie, R., Loh, Y. P., & Salton, S. R. J. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0027 · Cited by 348
Self-citationHypertension from targeted ablation of chromogranin A can be rescued by the human ortholog
Mahapatra, N. R., O’Connor, D. T., Vaingankar, S. M., Hikim, A. P. S., Mahata, M., Ray, S., Staite, E., Wu, H., Gu, Y., Dalton, N., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24354 · Cited by 309
Self-citationAntimicrobial peptides: natural effectors of the innate immune system
Radek, K., & Gallo, R. (2007) · Seminars in Immunopathology · doi:10.1007/s00281-007-0064-5 · Cited by 275
Borovac, J. A., D'Amario, D., Bozic, J., & Glavas, D. (2020) · World Journal of Cardiology · doi:10.4330/wjc.v12.i8.373 · Cited by 195
Marotta, V., Zatelli, M. C., Sciammarella, C., Ambrosio, M. R., Bondanelli, M., Colao, A., & Faggiano, A. (2018) · Endocrine-Related Cancer · doi:10.1530/erc-17-0269 · Cited by 161
Aung, G., Niyonsaba, F., Ushio, H., Kajiwara, N., Saito, H., Ikeda, S., Ogawa, H., & Okumura, K. (2011) · Immunology · doi:10.1111/j.1365-2567.2010.03395.x · Cited by 89
Pasqua, T., Mahata, S., Bandyopadhyay, G. K., Biswas, A., Perkins, G. A., Sinha-Hikim, A. P., Goldstein, D. S., Eiden, L. E., & Mahata, S. K. (2016) · Cell and Tissue Research · doi:10.1007/s00441-015-2316-3 · Cited by 53
“2008), the anti-adrenergic (Mahata et al. 2003; Mahata, et al. 2010; Mahata et al. 1997), anti-hypertensive (Mahapatra et al.”
Self-citation
Metadata
- Authors
- Mahata, S. K., O'Connor, D. T., Mahata, M., Yoo, S. H., Taupenot, L., Wu, H., Gill, B. M., & Parmer, R. J.
- Venue
- Journal of Clinical Investigation
- Published
- 1997-09-15
- Volume
- 100
- Issue
- 6
- Pages
- 1623-1633
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2003049002
- Cited by
- 394
- References
- 35
- FWCI
- 3.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.